Allworth Financial LP Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Allworth Financial LP boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 46.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 686 shares of the medical equipment provider’s stock after purchasing an additional 216 shares during the quarter. Allworth Financial LP’s holdings in Hologic were worth $40,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its holdings in shares of Hologic by 22.3% during the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 335 shares during the last quarter. SG Americas Securities LLC increased its position in Hologic by 116.6% during the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider’s stock valued at $594,000 after buying an additional 5,172 shares in the last quarter. Groupama Asset Managment raised its stake in Hologic by 63.4% in the fourth quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider’s stock valued at $3,918,000 after buying an additional 21,037 shares during the last quarter. Signaturefd LLC boosted its holdings in Hologic by 34.5% in the fourth quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider’s stock worth $212,000 after acquiring an additional 754 shares in the last quarter. Finally, Brevan Howard Capital Management LP boosted its holdings in Hologic by 85.5% in the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider’s stock worth $1,401,000 after acquiring an additional 8,960 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent analyst reports. Royal Bank Of Canada lowered their target price on shares of Hologic from $75.00 to $70.00 and set a “sector perform” rating for the company in a research note on Friday, May 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, May 5th. Evercore ISI upped their target price on Hologic from $62.00 to $68.00 and gave the company an “in-line” rating in a research report on Tuesday, July 8th. Finally, Morgan Stanley lowered their price target on Hologic from $77.00 to $65.00 and set an “equal weight” rating for the company in a research report on Monday, May 5th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Hologic presently has an average rating of “Hold” and an average price target of $77.33.

Insider Transactions at Hologic

In other news, Director Martin D. Madaus bought 5,445 shares of the firm’s stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director directly owned 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.88% of the company’s stock.

Hologic Stock Down 0.0%

Shares of HOLX stock opened at $63.99 on Friday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The stock has a market cap of $14.26 billion, a P/E ratio of 27.00, a P/E/G ratio of 2.35 and a beta of 0.55. The stock has a 50 day moving average of $62.46 and a 200 day moving average of $63.25. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm earned $1.03 EPS. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.